Identifying a blood test to predict risk of deterioration of brain haemorrhage

Identification of novel biomarkers to predict early haematoma expansion after intracerebral haemorrhage

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN90048218

Enrollment

Registered

2015-02-13

Start date

2015-05-01

Completion date

Unknown

Last updated

2017-10-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intracerebral haemorrhage (haemorrhagic stroke) Circulatory System

Interventions

Blood sampling within 3 hours of onset of symptoms of intracerebral haemorrhage for proteomic analysis of novel biomarkers. Research brain imaging (CT scan) at 24-36 hour from symptoms onset for signs

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Diagnosis of primary ICH confirmed by CT brain scan 2. Ability to collect research blood sample within 3 h of symptom onset 3. Likely to survive beyond 24 h (e.g. GCS > 5) 4. ICH not felt to be secondary to an underling structural abnormality (vascular malformation, aneurysm, tumour) or trauma.

Exclusion criteria

Exclusion criteria: 1. Under 18 2. End of life (not expected to survive passed 24 h 3. Other concomitant condition 4. Participation in a CTIMP 5. Pregnancy

Design outcomes

Primary

Measure	Time frame
Identification of novel biomarkers for risk of early haematoma expansion after ICH and identification of a proteomic profile of plasma in hyperacute ICH patients who progress to haematoma expansion. This will be measured by analysis inflammatory biomarkers and proteomic profile of the baseline blood sample (taken within 3 hours of symptom onset).	—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026